Profile picture for Sergio Schwartzman, MD

Sergio Schwartzman, MD

Sergio Schwartzman, MD, is the Franchellie M. Cadwell Associate Professor of Clinical Medicine at Cornell Weill Medical College, and Associate Attending Physician at the New York Presbyterian Hospital and at the Hospital for Special Surgery in New York City. Dr. Schwartzman has authored or coauthored over 60 articles, abstracts, books, and book chapters concerning rheumatoid arthritis, lupus, autoimmune ophthalmic disease, and related topics. Dr. Schwartzman is the recipient of The Fellows Award presented by the Northeast Regional American Rheumatism Association and The Franchellie M. Cadwell Chair. His current research interests spans the spondyloarthritis group of diseases, including understanding the microbiome in this group of illnesses, defining and treating autoimmune diseases of the eye, including uveitis, vasculitis, scleritis, and autoimmune orbital inflammatory disease and rheumatoid arthritis.

Articles By Sergio Schwartzman, MD

eye%20exa.jpg (keep)

My Take on New Ocular Screening Guidelines for Plaquenil

By Sergio Schwartzman, MD

A recent article published by the American Academy of Ophthalmology presented new recommendations for screening of patients being managed with hydroxychloroquine that changed the previous monitoring paradigm. More importantly, it has repositioned hydroxychloroquine from one of the safest medications that rheumatologists use to a drug that can have potentially significant ocular morbidity (if used in doses greater than 5 mg per kilogram and or for prolonged periods of time).

Read Article
eye%20exa.jpg (keep)

My Take on New Ocular Screening Guidelines for Plaquenil

By Sergio Schwartzman, MD

A recent article published by the American Academy of Ophthalmology presented new recommendations for screening of patients being managed with hydroxychloroquine that changed the previous monitoring paradigm. More importantly, it has repositioned hydroxychloroquine from one of the safest medications that rheumatologists use to a drug that can have potentially significant ocular morbidity (if used in doses greater than 5 mg per kilogram and or for prolonged periods of time).

Read Article
iritis-uveitis-e1333867439592.jpg

Adalimumab Approved for Uveitis

By Sergio Schwartzman, MD

Autoimmune ophthalmic disease is a frequent challenge to rheumatologists from both a diagnostic and therapeutic perspective. Approved therapies are limited and have only been infrequently or comfortably utilized by rheumatologists and autoimmune ophthalmologists.

Read Article

Notes from the 2015 SPARTAN Meeting

By Sergio Schwartzman, MD

Dr. Schwartzman reviews the proceedings of the 2015 Annual SPARTAN conference devoted to advances in spondyloarthritis.

Read Article
×